close icon

Experian to Drop 35% Before Uptrend Can Resume

Like most technology firms, Experian adapted to the new work-from-home environment relatively quickly. The Irish data and analytics company even managed to grow its revenue in 2020, even though its EPS didn’t change much from 2019.

After the initial coronavirus selloff in March, the stock swiftly recovered, as well. EXPN.L is currently hovering around 2900 pence a share, not too far below its November all-time high of 3192. Given Experian’s margins and cash-generating abilities, the company’ long-term future looks bright. In the mid-term, however, the stock appears vulnerable.

Experian stock can lose 35% in Elliott Wave Correction

Experian ‘s P/E ratio of 38 suggests it’s overvalued to begin with, but the Elliott Wave chart above makes the danger much more imminent. It reveals that a clear five-wave impulse has been in progress since the October 2008 bottom.

Elliott Wave Analysis Makes Experian ‘s Valuation Problem Obvious

The pattern, which managed to lift the price by 1177% over the following 12 years, is labeled (1)-(2)-(3)-(4)-(5). The impulsive structure of wave (3) is also visible. Wave 5 is the extended one, which explains why wave (4) retraced over 50% of (3), instead of the usual 38.2% Fibonacci.

If this count is correct, the recovery from 1823 to 3192 fits in the position of the final wave (5). ‘Final’, because according to the theory, every impulse is followed by a three-wave correction in the opposite direction. Besides, the RSI indicator shows a strong bearish divergence between waves (3) and (5).

The analysis so far makes us think this is not a good time to join the bulls in Experian. After a complete impulse pattern, the bears are often aiming at the support of the fourth wave. Here, this means a decline to roughly 1800 pence a share can be expected. The stock can lose ~35% in the next year or two.

Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

Lockheed ‘s Correction Still Unfolding as Expected

Almost a year and a half ago, in July 2019, we wrote that Lockheed Martin is likely “setting the stage for an unpleasant surprise.” The stock had just reached a new all-time high and was trading at $370 a share. Optimism was in the air and analysts were more bullish than ever. An indeed, fundamentally,…

Read More »

More analyses